Search

Your search keyword '"Concin, Nicole"' showing total 170 results

Search Constraints

Start Over You searched for: Author "Concin, Nicole" Remove constraint Author: "Concin, Nicole" Database Unpaywall Remove constraint Database: Unpaywall
170 results on '"Concin, Nicole"'

Search Results

2. Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

4. Lymph node staging in grade 1–2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?

5. Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal study

6. TP008/#1500 Trial in progress: phase 2/3 study of navtemadlin as maintenance therapy in patients with advanced or recurrent endometrial cancer who responded to chemotherapy (ENGOT-EN21; GOG-3089)

7. Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – An international pooled analysis of three ESGO accredited centres

8. Gestational choriocarcinoma

9. #84 Trial in progress: a phase 2/3 study of navtemadlin as maintenance therapy in patients with advanced or recurrent endometrial cancer (EC) who responded to chemotherapy (ENGOT-En21 and GOG-3089)

10. #809 Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients– an international pooled analysis of three ESGO accredited centers

11. #450 Surgical management of malignant intestinal obstruction in patients with ovarian cancer – ten-year experience of a tertiary gynecologic oncology department

12. #644 Surgical management of FIGO stage IV epithelial ovarian cancer versus FIGO stage IIIC: the real-world experience from KEM

13. Prognostic factors in patients with uterine sarcoma: the SARCUT study

14. Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients

15. Supplementary figures from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

16. Data from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

17. Supplementary Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

18. Data from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

19. Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

20. Supplementary figures from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

21. Supplementary Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

22. Supplementary Figure 1 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

23. Supplementary Figure 2 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

25. Data from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer

26. Supplementary Table 1 from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer

27. Supplementary Figure 1 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

28. Data from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer

29. Supplementary Figure 3 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

30. Supplementary Tables 1-3, Figure Legends 1-3 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

31. Supplementary Figure 2 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

32. Supplementary Table 1 from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer

33. Supplementary Tables 1-3, Figure Legends 1-3 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

34. Supplementary Figure 3 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

35. Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer

36. Lymph Node Staging in Grade 1-2 Endometrioid Ovarian Carcinoma Apparently Confined to the Ovary: Is it Worth?

37. Endometrial carcinosarcoma

38. Gender-related differences in career development among gynecologic oncology surgeons in Europe. European Network of Young Gynecologic Oncologists’ Survey based data

39. TP036/#426 Uplift (ENGOT-OV67/GOG-3048) a pivotal cohort of the XMT-1536–1 trial of upifitamab rilsodotin (XMT-1536; UPRI), a NAPI2B-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer

40. 2022-RA-1515-ESGO Impact of surgical staging on survival of low grade endometrioid ovarian cancer apparently confined to the ovary

41. 2022-RA-1008-ESGO The impact of cytoreductive surgery in FIGO IV and recurrent endometrial cancer

42. 2022-RA-853-ESGO Analysis of the gender distribution among the invited speakers at European society of gynaecological oncology (ESGO) biannual congresses 2017, 2019, and 2021

43. 2022-RA-1402-ESGO Implementing HRD testing in routine clinical practice among patients with primary high-grade advanced ovarian cancer

44. 2022-RA-459-ESGO UPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer

45. 2022-RA-831-ESGO Gender-related differences in career development among gynecologic oncology surgeons in europe. European network of young gynecologic oncologists’ survey based data

46. 2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies

48. Impact of substage and histologic type in stage I ovarian carcinoma survival: a multicenter retrospective observational study

50. UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in platinum-resistant ovarian cancer (585)

Catalog

Books, media, physical & digital resources